← All trials
NCT04328272
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 28, 2020
- Primary completion
- May 28, 2020
- Completion date
- Jun 28, 2020
- First posted
- Mar 31, 2020
- Last posted
- Apr 2, 2020
- Enrollment
- 75
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of IowaLead sponsor
- Ayub Medical College, AbbottabadSponsor investigator
- Ayub Medical College, AbbottabadCollaborator
- Khyber Medical University PeshawerOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.